A

Alnylam Pharmaceuticals

Develops RNAi-based therapies for genetic diseases

Vice President Global Scientific Communications

Biology & BiotechConfirmed live in the last 24 hours
Full-timeCambridge, MA, USA$332k - $448kIn-person

About the Job

Requirements

  • An advanced scientific or clinical degree (MD, PharmD, PhD, or equivalent) is required.
  • At least 15 years of progressive experience in Medical Communications, Publications, Medical Affairs, Scientific Communications, or related functions within the pharmaceutical or biotechnology industry is required.
  • Significant people leadership experience, including management of large, complex, and geographically dispersed teams, is required.
  • Demonstrated success developing and executing global publication and scientific communication strategies is required.
  • Extensive experience leading publication planning, publication committees, and scientific dissemination activities is required.
  • Expertise engaging key opinion leaders, academic investigators, and professional societies is required.
  • Deep understanding of ICMJE, GPP, publication ethics, authorship standards, and industry regulations is required.
  • Significant experience planning and leading major international scientific congresses is required.
  • Strong executive presence and communication, collaboration, and influencing skills are required.

Responsibilities

  • Develop and execute the long-term integrated global strategy for Medical Communications, Publications, and Medical Information aligned with corporate and Medical Affairs objectives.
  • Partner as a key member of the Medical Affairs Leadership Team to define strategy and drive organizational development.
  • Build and retain a scientific communications organization focused on innovation, excellence, compliance, and scientific rigor.
  • Interact with key societies and organizations related to publications and congresses.
  • Establish and chair publication governance structures and publication committees.
  • Drive innovation in scientific engagement, digital communications, and omnichannel medical education approaches.
  • Act as a senior scientific representative and thought leader to key external stakeholders.
  • Foster a culture of scientific excellence, accountability, innovation, collaboration, and continuous learning.
  • Build organizational capabilities to support continued growth and an expanding portfolio.
  • Lead an integrated medical channel and content strategy, ensuring scientific content from Medical Communications, Publications, and Medical Information is built efficiently and used across digital, field medical, and other medical affairs channels.
  • Establish an integrated strategy for scientific and healthcare partnerships, grants, and sponsorships, building trusted, compliant relationships with health systems, professional societies, and patient organizations across the portfolio and ahead of upcoming launches.

Desired Qualifications

  • Experience within rare disease, specialty medicine, cardiovascular, neurology, or RNAi therapeutics is preferred.
  • Demonstrated success building and transforming high-performing scientific communications organizations is preferred.
  • Experience interacting with journal editors, editorial boards, and leading scientific publications is preferred.
  • Global experience supporting multiple regions and cross-functional teams is preferred.

About the Company

Alnylam Pharmaceuticals

Develops RNAi-based therapies for genetic diseases

Alnylam Pharmaceuticals develops RNA interference (RNAi) therapeutics to silence disease-causing genes, aiming to treat rare genetic disorders. Its products work by using RNA molecules that block gene expression, reducing the impact of specific genetic diseases. The company differentiates itself by concentrating on RNAi-based drugs for rare diseases and by building a pipeline through large clinical programs and strategic partnerships, such as commercialization deals in the Gulf States and collaborations with investors. Revenue comes from approved drug sales, licensing agreements, strategic collaborations, and related services like genetic testing and counseling. The company’s goal is to advance and commercialize RNAi therapies to improve outcomes for patients with genetic disorders, expanding its portfolio through partnerships and investments.

Company size
1,001-5,000
Company stage
IPO
Headquarters
Cambridge, MA
Founded
2002

Recently Posted Jobs

Explore more opportunities at Alnylam Pharmaceuticals

See more jobs